Loading
A phase 3 trial of Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, now recruiting.
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC is a phase 3 interventional study registered as NCT07720284 by AstraZeneca, with 915 participants planned, started 2026-07-16 and due to reach its primary completion in 2030-09-11. Interventions recorded: Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab and Enfortumab vedotin.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Daiichi Sankyo, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.